作　　者： (于之清）; (童武）; (郑浩）; (李国新）; (高飞）; (王涛）; (梁超）; (叶超）; (武吉强）; (黄勤峰）; (童光志）;

机构地区： 中国农业科学院上海兽医研究所,上海200241

出　　处： 《中国动物传染病学报》 2017年第4期6-12,共7页

摘　　要： 本研究使用CRISPR/Cas9基因编辑技术结合同源重组,以伪狂犬病毒经典疫苗株Bartha-K61为骨架,将其gB基因替换为伪狂犬病毒变异株JS-2012的gB基因,经噬斑纯化、PCR筛选鉴定,获得重组病毒r PRV-BJB。体外生物学特性分析结果显示,重组病毒株r PRV-BJB与疫苗株Bartha-K61具有相似的生长特性和噬斑形态,可作为新型重组伪狂犬病病毒疫苗候选株。 In this study, we utilized the specific CRISPR/Cas9 gene editing system combined with homologous recombination to replace the gB of Bartha-K61 strain with that of JS-2012 strain. After several rounds plaque purification and PCR-screening, the acquired recombinant virus was identified by sequencing and designated as r PRV-BJB. r PRV-BJB and Bartha-K61 showed similar biological characteristics in vitro, indicating that r PRV-BJB is a promising PRV vaccine candidate that can be performed in following protective efficacy evaluation.

关 键 词： 变异伪狂犬病毒 重组病毒 基因